Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Interim phase II data for isatuximab in refractory/relapsed multiple myeloma

Dec. 14, 2015

Anti-HLA-DR antibody IMMU-114 demonstrates activity in first-in-human study

Dec. 14, 2015

Janssen starts first-in-human trial of Aduro's ADU-214 in patients with NSCLC

Dec. 14, 2015

DMC recommends continuation of phase III trial of AGS-003 in RCC following second interim analysis

Dec. 14, 2015

Preclinical efficacy of first-in-class TCB antibody EM-801

Dec. 14, 2015

First patient dosed in phase I/II study of NKTR-214

Dec. 11, 2015

ISA-101 assessed in phase II combination trial with checkpoint inhibitor nivolumab

Dec. 10, 2015

IL-15N72D/IL-15Ralpha-Fc superagonist complex shows promise for high-risk hematologic malignancies

Dec. 9, 2015

Amgen and Merck & Co. form cancer immunotherapy collaboration

Dec. 9, 2015

Morphotek and University of Wisconsin-Madison to study farletuzumab

Dec. 7, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...